新型成人慢性特发性便秘治疗药物乳糖醇  

A new therapeutic agent for adult chronic idiopathic constipation,lactitol

作　　者：李少强 李健春 张亚同[2] 胡欣[2] LI Shao-qiang;LI Jian-chun;ZHANG Ya-tong;HU Xin(Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Science,Peking University,Beijing 100083,China;Department of Pharmacy,National Center of Geriatrics,Assessment of Clinical Drugs Risk and Individual Application Key Laboratory,Beijing Hospital,Beijing 100730,China)

机构地区：[1]北京大学药学院药事管理与临床药学系,北京100083 [2]北京医院药学部,国家老年医学中心,药物临床风险与个体化应用评价北京市重点实验室,北京100730

出　　处：《中国新药杂志》2021年第16期1451-1455,共5页Chinese Journal of New Drugs

摘　　要：乳糖醇(lactitol)于1985年由诺华公司首次在瑞士注册,商品名为Importal,用于肝性脑病引起的高氨血症。2020年2月12日获美国FDA批准用于治疗成人慢性特发性便秘,商品名为Pizensy。lactitol可增加患者排便频率,治疗成人慢性特发性便秘不劣于鲁比前列酮。其最常见的不良反应为上呼吸道感染、腹胀、腹泻等。本文对lactitol的作用机制、药动学、有效性、安全性等进行综述。Lactotol was first registered by Novartis in Switzerland in 1985.Its trade name is Importal.It is used for the treatment of hyperammonemia caused by hepatic encephalopathy.On February 12,2020,it was approved by the US FDA for the treatment of chronic idiopathic constipation in adults.Its trade name is Pizensy.Latitol can increase the defecation frequency of patients,and the treatment efficacy for chronic idiopathic constipation in adults is not inferior to that of rubiprostone.The most common adverse reactions are upper respiratory tract infection,abdominal distension and diarrhea.The mechanism of action,pharmacokinetics,effectiveness,and safety of lactitol were reviewed in this article.

关 键 词：乳糖醇 成人慢性特发性便秘 临床疗效 

分 类 号：R975.3[医药卫生—药品]